Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Beyond the Genome 2012

Open Access Poster presentation

Next-generation sequencing at Merck-Boston

Richard Stevens

  • Correspondence: Richard Stevens

Author Affiliations

Affiliation: tbc

BMC Proceedings 2012, 6(Suppl 6):P36  doi:10.1186/1753-6561-6-S6-P36

The electronic version of this article is the complete one and can be found online at:

Published:1 October 2012

© 2012 Stevens; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Poster presentation

Next-generation sequencing (NGS) is quickly replacing other methods for determining expression profiling of RNA as well as single-nucleotide variations within the genomes of both model organisms and human samples. At the Boston facility of Merck Research Laboratories, we concentrate on preparation and sequencing of samples where the research needs cannot be met by commercial venders. These unmet needs may be due to either availability of up-to-date protocols or to deadline constraints. In addition to validating and developing new library-construction and sequencing protocols, we also evaluate commercial vendors in consideration for future outsourcing. One of these current projects is an evaluation of transcriptome sequencing and profiling of formalin fixed paraffin embedded (FFPE) samples from Merck's current and past clinical studies. FFPE samples are readily available and easily stored but create difficulties in NGS analysis due to the low quality of the purified nucleic acids. Here, we compare techniques for transcriptome sequencing to microarray profiling of RNA purified from FFPE tissues as well as their mirrored fresh frozen counterparts.